This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Anacor Pharma Remains Over-Valued on Development of Inferior Drugs

Anacor Pharmaceuticals (ANAC) shares are down 35% since the middle of March when biotech stocks starting selling off, but the company's $600 million-plus market value is still bloated. Anacor is waiting to hear from the FDA on an approval decision (expected July 29) for the toenail fungus drug tavaborole. If approved, tavaborole is likely to be a commercial disappointment for reasons I've outlined previously. In this column, I want to explain why Anacor's second pipeline product, the experimental psoriasis/atopic dermatitis drug AN2728, also faces commercial risk from competitors Regeneron Pharmaceuticals (REGN) and Celgene (CELG).

In general, both Regeneron's dupilumab and Celgene's apremilast (recently approved for psoriatic arthritis and marketed as Otezla) generate robust decreases in the severity of atopic dermatitis, although neither company conducted particularly large studies. If we define treatment benefit as a 50% decrease in the Eczema Area and Severity Index (EASI), the success rate for dupilumab was 86%. Apremilast was a little less effective with only about 62% of the patients achieving a greater than 50% decrease in the EASI score. While trial size differences make the error bar around these estimates large, dupilumab appears to have an efficacy edge over apremilast. How do these results compare to Anacor's AN2728?

Anacor measured the benefit of AN2728 in atopic dermatitis using an endpoint known as the Investigator's Static Global Assessment (ISGA), which makes a comparison to the dupilumab and apremilast data more difficult. For argument's sake, I'm going to equate the achievement of an ISGA score of 0 or 1 with at least a two-point improvement as similar to a 50% decrease in EASI score.

Across two studies, the AN2728 results appear less robust than what was reported in the Regeneron and Celgene studies. In Anacor's AD-203 trial, treatment with AN2728 generated a 35% success rate. AN2728 did better in the AD-102 trial where treatment was successful in about 47% of the atopic dermatitis patients. Again, these cross-trial and cross-endpoint comparisons are not precise, but AN2728 appears to be less effective than apremilast and dupilumab. It should also be noted that Celgene is currently testing a higher dose of apremilast in atopic dermatitis, so the drug's efficacy could improve even further. 

AN2728 is a topical medication, so more convenient than the injectable dupilumab but without much advantage over the oral apremilast. On the safety front, neither dupilumab nor apremilast have generated any safety signals, where severe adverse events were numerically fewer in the dupilumab arm and all of the adverse events in the apremilast study were grade 1. This essentially means that commercial success will likely be driven by efficacy differences and perhaps convenience, where AN2728 appears disadvantaged on efficacy but may have a convenience benefit versus dupilumab.

Anacor recently moved AN2728 into phase III studies for atopic dermatitis. Like with toenail fungus drug tavaborole, existing data suggest AN2728 is an inferior drug relative to the competition. The significant risks inherent with both of Anacor's lead drugs are not yet reflected in the company's over-valued stock price.

Sobek is long Celgene and no positions in Regeneron or Anacor. 

David Sobek has been writing on biotech for a number of years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvnia State Univeristy in 2003 and a BA in international relations from The College of William and Mary in 1997.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs